PUBLISHER: Visiongain Reports Ltd. | PRODUCT CODE: 1093671
PUBLISHER: Visiongain Reports Ltd. | PRODUCT CODE: 1093671
Title:
Artificial Intelligence (AI) in Drug Discovery Market Report 2022-2032
Forecasts by Offering (AI Software, AI Services), by Technology (Deep Learning, Supervised Learning, Reinforcement Learning, Unsupervised Learning, Other), by Applications (Oncology, Infectious Diseases, Neurological Disorders, Metabolic Diseases, Cardiovascular Diseases, Other), by Type (Target Identification, Molecule Screening, Drug Design and Drug Optimisation, Preclinical and Clinical Testing) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Recovery Scenarios.
The Artificial Intelligence (AI) in Drug Discovery Market Report 2022-2032: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
Artificial intelligence (AI) is defined as a machine that employs modern technology to do tasks that are similar to those performed by the human mind. The primary purpose of drug discovery research is to find medications that can aid in the prevention or treatment of specific diseases. The difficulties of reviewing, obtaining, and utilising data to solve difficult medical problems fueled demand for artificial intelligence (AI) in the drug discovery business. The market for artificial intelligence in drug development is divided into offering, technology, type, applications, and region. The growing number of cross-industry collaborations and partnerships, the increasing need to control drug discovery & development costs and reduce overall time taken in this process, the rising adoption of cloud-based applications & services, and the impending patent expiration of blockbuster drugs are all driving the artificial intelligence in drug discovery market. On the other side, the market's expansion is being hampered by a paucity of data sets in the field of drug discovery and an insufficient supply of competent workers.
The shortage of data is a reoccurring issue in all industries that are deploying AI. A standard biological investigation requires a minimum of five samples to be legitimate. Meanwhile, in order to function well, most machine learning algorithms must be trained on hundreds of thousands of data points or samples. This is why obtaining high-quality healthcare data is critical something that has proven increasingly challenging over time. The challenge is due to the disorganised and fragmented health data scattered across many data platforms and organisations. Patients' insurance and healthcare providers change too frequently, making data collection difficult.
This report tells you TODAY how the artificial intelligence (AI) in drug discovery market will develop in the next 10 years, and in-line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, V, L, W and U are discussed in this report.
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 4 regional and 20 leading national markets:
The report also includes profiles and for some of the leading companies in the Artificial Intelligence (AI) in Drug Discovery Market, 2022 to 2032, with a focus on this segment of these companies' operations.
Overall world revenue for Artificial Intelligence (AI) in Drug Discovery Market, 2022 to 2032 in terms of value the market will surpass US$919 million in 2022, our work calculates. We predict strong revenue growth through to 2032. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
In summary, our 461-page report provides you with the following knowledge:
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Artificial Intelligence (AI) in Drug Discovery Market, 2022 to 2032 Market and leading companies. You will find data, trends and predictions.
Visiongain is a trading partner with the US Federal Government.